Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin kappa variable 2-24 (IGKV2-24) is a gene segment encoding the variable region of the kappa light chain in immunoglobulins (antibodies)[1][2][4][5][6]. This variable domain participates in antigen recognition and is generated by V-(D)-J recombination during B cell development, contributing to the diversity of antibodies in the adaptive immune system[2][5]. IGKV2-24 is not a stand-alone receptor, enzyme, or direct therapeutic target, but is a functional part of the antibody molecules either as membrane-bound B cell receptors or as secreted antibodies. Its main role is in forming the antigen-binding site in conjunction with immunoglobulin heavy chains, playing a central part in humoral immunity[2][4][5][6]. It is relevant in clinical immunology for evaluating B cell clonality and may be implicated in studies of immune repertoire or diagnostics but is not directly targeted by drugs[2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin kappa variable 2-24 (IGKV2-24).